It’s been awhile since Diabetic Investor had a contest and with all the interest in Afrezza we thought it was time for another. As we have noted there seems to be little middle ground on Afrezza, people either believe it’s the greatest thing since sliced bread and soft soap or they believe it is nothing more than a niche product. With passion running high on both sides and nothing better than a little, more like a lot, of passion let’s get this contest started.
So here are the rules – first predict total first years sales for Afrezza. Next predict where MannKind’s (NASDAQ:MNKD) share price will be at the end of the year. Third should you believe that Sanofi (NYSE:SNY) will end their partnership with MannKind predict when this will happen. Finally and this should be the most fun come up with some new ways for the folks on Twitter to call Diabetic Investor an idiot.
Seriously we’re getting a little bored being told that we’re short MannKind stock, we’re not and in fact don’t own a single share long or short. It’s also not very creative to say that Diabetic Investor is getting paid to bash MannKind and Afrezza. We wish we were but that would be just too much to ask. As regular readers know one of our mantras is if you want a friend get a dog. This is about the business of diabetes and not about whether Afrezza works or not.
We had thought about perhaps excluding anyone who works at that three ring circus known as Sanofi but thought why exclude these people. Heck it’s only fair that my good buddy Serge and his buddies should have a chance to bash Diabetic Investor. That being said it’s also fair that we let anyone associated with MannKind bash away.
Now it terms of prizes the winner or winners will receive their choice of a bottle of wine, a case of Miller Lite or a bottle of Grey Goose. So there it is have fun everyone.